




Coevolución

Dr. Luis Castañeda




Coevolución




~ 200 MYA !!!

Coevolución


(A) Specific coevolution



(B) Diffuse coevolution





(C) Escape-and-radiate coevolution



Coevolución

Cambio genético recíproco en especies que interactúan entre ellas debido a la selección natural impuesta por cada una de ellas sobre la otra especie (Futuyma & Kirkpatrick 2017).




Hipótesis de la Reina Roja

“No importa que tan rápido corras, siempre estarás en el mismo lugar”




“Para un sistema evolutivo, la mejora continua es necesaria para sólo mantener su ajuste a los sistemas con los que está coevolucionando”

Hipótesis de la Reina Roja




Coevolución parasito-humano


a Bacterial transformation



b Bacterial transduction



c Bacterial conjugation




Copyright © 2006 Nature Publishing Group
Nature Reviews | Microbiology

Tasa mutacional
bacterias

$$3 \times 10^{-5}$$

Tasa mutacional
humanos


$$1 \times 10^{-8}$$




Humanos y especies asociadas



Humanos y especies asociadas



A map of diversity in the human microbiome




Streptococcus dominates the oral cavity with *S. mitis* > 75% in the **cheek**

Propionibacterium acnes lives on the skin and **nose** of most people



Many *Corynebacterium* species characterize different body sites:


C. matruchoti
the plaque
C. accolens
the nose
C. croppenstedtii
the skin



Lactobacillus species (*L. gasseri*, *L. jensenii*, *L. crispatus*, *L. iners*) are predominant but mutually exclusive in the **vagina**



Staphylococcus epidermidis colonizes external body sites



○ Commensal microbes
★ Potential pathogens

The four most abundant phyla


- Actinobacteria
- Bacteroidetes
- Firmicutes
- Proteobacteria

Low abundance phyla


- Chloroflexi
- Cyanobacteria
- Euryarchaeota
- Fusobacteria
- Lentisphaerae
- Spirochaetes
- Synergistetes
- Tenericutes
- Thermi
- Verrucomicrobia

National Institutes of Health
Human Microbiome Project

N. Segata & C. Huttenhower
<http://huttenhower.sph.harvard.edu>
(reproduced with CC-BY and not for sale from Microbiome Analysis)



Several *Prevotella* species are present in the gastrointestinal tract. *P. copri* is present in 19% of the subjects and dominates the **intestinal** flora when present




Microscopy from <http://kcmmap.athabasca.ca>

Bacteroides is the most abundant genus in the **gut** of almost all healthy subjects




Campylobacter includes opportunistic pathogens, but members live in the oral cavities of most healthy people in the cohort




E. coli is present in the **gut** of the majority of healthy subjects but at very low abundance


Microbiota intestinal en humanos



Microbiota intestinal en humanos



Microbiota en humanos



B. Mechanisms in microbially-induced obesity


Energy intake & fat storage

↑ SCFAs

- lipogenesis
- appetite regulation

Low-grade systemic inflammation



↑ LPS



Coevolución microbioma-humano

Rapid changes in the gut microbiome during human evolution


Andrew H. Moeller^{a,b}, Yingying Li^{c,d}, Eitel Mpoudi Ngole^e, Steve Ahuka-Mundike^{f,g}, Elizabeth V. Lonsdorf^{h,i}, Anne E. Pusey^j, Martine Peeters^g, Beatrice H. Hahn^{c,1}, and Howard Ochman^{b,1}



Coevolución microbioma-humano

Human and *Helicobacter pylori* coevolution shapes the risk of gastric disease


Nuri Kodaman^{a,b,1}, Alvaro Pazos^{c,1}, Barbara G. Schneider^{d,2}, M. Blanca Piazuelo^d, Robertino Mera^d, Rafal S. Sobota^{a,b}, Liviu A. Sicinski^e, Carrie L. Shaffer^f, Judith Romero-Gallo^d, Thibaut de Sablet^d, Reed H. Harder^b, Luis E. Bravo^g, Richard M. Peek, Jr.^d, Keith T. Wilson^{d,f,h,i}, Timothy L. Cover^{f,h,i,j}, Scott M. Williams^{a,b,3}, and Pelayo Correa^{d,3}



Coevolución microbioma-humano

Age of the Association between *Helicobacter pylori* and Man

Yoshan Moodley^{1,2,3*}, Bodo Linz^{1,3,3*}, Robert P. Bond⁴, Martin Nieuwoudt⁴, Himla Soodyall⁵, Carina M. Schlebusch⁵, Steffi Bernhöft¹, James Hale⁶, Sebastian Suerbaum⁷, Lawrence Mugisha⁸, Schalk W. van der Merwe⁴, Mark Achtman^{1,6*}



Coevolución microbioma-humano

Transfer of carbohydrate-active enzymes from marine bacteria to Japanese gut microbiota

Jan-Hendrik Hehemann^{1,2,†}, Gaëlle Correc^{1,2}, Tristan Barbeyron^{1,2}, William Helbert^{1,2}, Mirjam Czjzek^{1,2} & Gurvan Michel^{1,2}




*Zobellia
galactanivorans*



*Bacteroides
plebeius*

Coevolución microbioma-humano



*Zobellia
galactanivorans*



*Bacteroides
plebeius*



Coevolución patógeno-humano



Coevolución entre humanos y patógenos que ha determinado los patrones de virulencia y transmisión de estos patógenos.

Coevolución patógeno-humano


Esquistosomiasis



- Dolor abdominal, diarrea.
- Falla renal y hepática, cáncer, déficit cognitivo.
- Baja virulencia, necesidad de un vector.

Coevolución patógeno-humano

Enfermedades zoonóticas



Alta virulencia

Coevolución patógeno-humano

- Un patógeno evolucionará hacia un equilibrio establecido por un compromiso entre su virulencia y su capacidad de transmisión.
- Esto maximizaría su capacidad de infectar nuevos hospederos.
- Patógenos altamente virulentos deben altamente transmisibles.
- Patógenos con baja virulencia pueden ser menos transmisibles.


Coevolución patógeno-humano

El compromiso entre virulencia y transmisión de un patógeno en un hospedero en particular dependerá tanto de factores asociados a ambas especies y de la historia coevolutiva entre ellas.


Classes of Human Pathogens

Taxonomic	Site of Propagation	Examples	Diseases
Prions	Intracellular	Prion protein	Creutzfeld- Jacob Disease
Viruses	Obligate Intracellular	Poliovirus	Poliomyelitis
Bacteria	1. Obligate Intracellular 2. Extracellular 3. Facultative intracellular	1. Chlamydia trachomatis 2. Strep pneumoniae 3. TB	Trachoma Pneumonia Tuberculosis
Fungi	1. Extracellular 2. Facultative intracellular	1. Candida albicans 2. Histoplasma capsulatum	Thrush Histoplasmosis
Protozoa	1. Extracellular 2. Facultative intracellular 3. Obligate intracellular	1. Trypanosoma gambiense 2. T. cruzi 3. Leishmania donovani	1. Sleeping sickness 2. Chagas dse 3. Kala- azar
Helminths	1. Extracellular 2. Intracellular	1. Wuchereria bancrofti 2. Trichinella spiralis	1. Filariasis 2. Trichinosis

Coevolución patógeno-humano



Coevolución patógeno-humano




- Baja mortalidad inmediata.
- Largo periodo asintomático que promueve la transmisión a través de contacto “directo” con infectados.

Coevolución patógeno-humano

Did the *Florida Dentist* infect his patients with HIV?



Phylogenetic tree of HIV sequences from the **DENTIST**, his Patients, & **Local HIV-infected People**:



From Ou et al. (1992) and Page & Holmes (1998)


Coevolución patógeno-humano

Mycobacterium tuberculosis




Coevolución patógeno-humano



- Peste
- *Yersenia pestis*
- Peste negra
- 1/3 población europea
- Roedor – Pulgas/Piojos



Coevolución patógeno-humano




Coevolución patógeno-humano



- Altamente contagioso.
- Alta mortalidad inmediata.
- Esta alta virulencia limita la habilidad del virus de dispersarse a un gran número de personas.
- Aislamiento y cuarentena son medidas efectivas para su control.


Coevolución patógeno-humano



Coevolución patógeno-humano


- Un patógeno evolucionará hacia un equilibrio establecido por un compromiso entre su virulencia y su capacidad de transmisión.
- Esto maximizaría su capacidad de infectar nuevos hospederos.
- Patógenos altamente virulentos deben altamente transmisibles.
- Patógenos con baja virulencia pueden ser menos transmisibles.

Coevolución patógeno-humano



- Tratamientos altamente agresivos podrían aumentar la virulencia.
- Tratamientos adaptativos podrían facilitar la competencia entre patógenos con distinto grado de virulencia.

Coevolución patógeno-humano



Coevolución patógeno-humano

CANCER: AN EVOLVING THREAT


EVOLVING STRATEGIES

Oncologists are adapting cancer-treatment strategies to take into account how a tumour evolves.

Stemming tumour growth


As cancer cells divide, new mutations emerge, establishing new cell populations that can be mapped on an evolutionary tree.

A therapy that targets mutations closer to the trunk has a better chance of eliminating cancer.



Adapting for balance

Cancer-cell populations compete, so completely killing cells that are sensitive to a particular drug lets resistant cells grow unfettered. Adjusting dosage according to tumour response could maintain balance in the populations.



The double bind

Developing resistance to one treatment can leave tumours vulnerable to others. Evolutionary modelling can suggest the best way to apply multiple therapies to almost eradicate resistant cells.

